Table 1.
Demographic and clinicopathologic features of endometrial cancers stratified by ERBB2 genetic alteration status. The number of cases in each category do not always sum up to the total number of cases in the cohort due to missing data values. amp, amplified; CN‐H/TP53abn, copy number‐high/TP53 abnormal; CN‐L/NSMP, copy number‐low/no specific molecular profile; FIGO, International Federation of Gynecology and Obstetrics; High‐grade EC‐NOS, high‐grade endometrial carcinoma, not otherwise specified; MSI‐H, microsatellite instability‐high; mut, mutated; non‐amp, non‐amplified; wt, wildtype.
| Characteristic | ERBB2 mutation/copy number status, N = 1859 | P‐value a | ||||
|---|---|---|---|---|---|---|
| wt/non‐amp, N = 1691, n (%) | mut/non‐amp, N = 58, n (%) | wt/amp, N = 99, n (%) | mut/amp, N = 11, n (%) | mut/non‐amp vs wt/non‐amp | mut/non‐amp vs wt/amp | |
| Age at diagnosis [median, years (range)] | 63 (21–96) | 60 (31–83) | 66 (54–86) | 70 (54–75) | 0.041 | < 0.001 |
| BMI [median, kg·m−2, (range)] | 29.7 (14.9–67.6) | 28.0 (16.9–48.4) | 28.3 (19.3–48.2) | 29.3 (21.6–52.7) | 0.08 | 0.95 |
| Stage (FIGO 2009) | ||||||
| I | 906 (59) | 40 (71) | 25 (29) | 3 (33) | 0.22 | < 0.001 |
| II | 65 (4.2) | 3 (5.4) | 4 (4.7) | 1 (11) | ||
| III | 309 (20) | 9 (16) | 24 (28) | 2 (22) | ||
| IV | 251 (16) | 4 (7.1) | 32 (38) | 3 (33) | ||
| Histologic type | ||||||
| Endometrioid | 948 (56) | 38 (66) | 7 (7.1) | 1 (9.1) | 0.12 | < 0.001 |
| Serous | 233 (14) | 4 (6.9) | 34 (34) | 8 (73) | ||
| Clear cell | 47 (2.8) | 4 (6.9) | 5 (5.1) | 1 (9.1) | ||
| Carcinosarcoma | 196 (12) | 4 (6.9) | 25 (25) | 1 (9.1) | ||
| Mixed/high‐grade EC‐NOS | 140 (8.3) | 6 (10) | 23 (23) | 0 (0) | ||
| Undifferentiated/de‐differentiated | 36 (2.1) | 2 (3.4) | 1 (1.0) | 0 (0) | ||
| Unclassifiable | 91 (5.4) | 0 (0) | 4 (4.0) | 0 (0) | ||
| FIGO grade (for endometrioid only) | ||||||
| 1 or 2 | 741 (81) | 30 (79) | 5 (71) | 0 (0) | 0.84 | 0.64 |
| 3 | 175 (19) | 8 (21) | 2 (29) | 1 (100) | ||
| Molecular subtype | ||||||
| POLE | 95 (5.6%) | 6 (11%) | 0 | 0 | < 0.001 | < 0.001 |
| MSI‐H | 404 (24%) | 32 (59%) | 0 | 0 | ||
| CN‐L/NSMP | 561 (33%) | 7 (13%) | 8 (8.1%) | 1 (9.1%) | ||
| CN‐H/TP53abn | 631 (37%) | 9 (17%) | 91 (92%) | 10 (91%) | ||
a
Fisher exact test, two‐tailed.